Biotech

All Articles

OS Treatments refiles $6M IPO to finance HER2 drug, preclinical ADCs

.Operating system Therapies will list on the NYSE American stock swap this morning via a $6.4 thousa...

ALX's fizzling CD47 feedback cost delivers inventory spiraling down

.ALX Oncology's phase 2 gastric cancer cells reaction rate has compromised. After seeing its CD47 bl...

Ionis axes eye condition coming from targets of Roche-partnered possibility after records disappoint

.An Additional of Ionis Pharmaceuticals' key midphase readouts has actually disappointed desires, ur...

Biogen's CEO pointed out no dangerous deals in 2023. He prepares to be daring

.While Biogen's pharma peers are actually looking for late-stage resources along with little bit of ...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Biography has actually been actually a biotech searching for a pipe after it junked its lead...

Biogen bows out Denali Alzheimer's collab

.Biogen has actually returned legal rights to an early Alzheimer's illness plan to Denali Therapies,...

Takeda faucets brand new head people oncology business-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial leadership hirings, firings and r...

Vertex, hammered by AATD again, loses 2 assets on throw away pile

.Tip's effort to handle a rare hereditary disease has actually reached an additional setback. The bi...

Vir gains 3 T-cell engagers coming from Sanofi, gives up 25% of workers

.Vir Medical's second-quarter profits document wasn't except large information. The provider welcome...

Galapagos pauses CAR-T cell treatment litigation over Parkinsonism scenario

.Galapagos has actually paused registration in a trial of a BCMA-directed CAR-T cell treatment, pump...